TNDM Quote, Financials, Valuation and Earnings

Beta Bionics has a net margin of -55.69% compared to Tandem Diabetes Care's net margin of --. Tandem Diabetes Care's return on equity of -81.14% beat Beta Bionics's return on equity of --.

Tandem Diabetes Care has a consensus price target of $38.29, signalling upside risk potential of 91.62%. On the other hand Beta Bionics has an analysts' consensus of $25.71 which suggests that it could grow by 130.83%. Given that Beta Bionics has higher upside potential than Tandem Diabetes Care, analysts believe Beta Bionics is more attractive than Tandem Diabetes Care.

Tandem Diabetes Care has a beta of 1.474, which suggesting that the stock is 47.439% more volatile than S&P 500. In comparison Beta Bionics has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Tandem Diabetes Care has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Beta Bionics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Tandem Diabetes Care pays -- of its earnings as a dividend. Beta Bionics pays out -- of its earnings as a dividend.

Tandem Diabetes Care quarterly revenues are $234.4M, which are larger than Beta Bionics quarterly revenues of --. Tandem Diabetes Care's net income of -$130.6M is higher than Beta Bionics's net income of --. Notably, Tandem Diabetes Care's price-to-earnings ratio is -- while Beta Bionics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Tandem Diabetes Care is 1.34x versus -- for Beta Bionics. Usually stocks with elevated PS ratios are considered overvalued.

Boston Scientific has a net margin of -55.69% compared to Tandem Diabetes Care's net margin of 14.45%. Tandem Diabetes Care's return on equity of -81.14% beat Boston Scientific's return on equity of 8.96%.

Tandem Diabetes Care has a consensus price target of $38.29, signalling upside risk potential of 91.62%. On the other hand Boston Scientific has an analysts' consensus of $116.12 which suggests that it could grow by 12.53%. Given that Tandem Diabetes Care has higher upside potential than Boston Scientific, analysts believe Tandem Diabetes Care is more attractive than Boston Scientific.

Tandem Diabetes Care has a beta of 1.474, which suggesting that the stock is 47.439% more volatile than S&P 500. In comparison Boston Scientific has a beta of 0.685, suggesting its less volatile than the S&P 500 by 31.536%.

Tandem Diabetes Care has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Boston Scientific offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Tandem Diabetes Care pays -- of its earnings as a dividend. Boston Scientific pays out -- of its earnings as a dividend.

Tandem Diabetes Care quarterly revenues are $234.4M, which are smaller than Boston Scientific quarterly revenues of $4.7B. Tandem Diabetes Care's net income of -$130.6M is lower than Boston Scientific's net income of $674M. Notably, Tandem Diabetes Care's price-to-earnings ratio is -- while Boston Scientific's PE ratio is 75.32x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Tandem Diabetes Care is 1.34x versus 8.75x for Boston Scientific. Usually stocks with elevated PS ratios are considered overvalued.

Intuitive Surgical has a net margin of -55.69% compared to Tandem Diabetes Care's net margin of 30.99%. Tandem Diabetes Care's return on equity of -81.14% beat Intuitive Surgical's return on equity of 15.82%.

Tandem Diabetes Care has a consensus price target of $38.29, signalling upside risk potential of 91.62%. On the other hand Intuitive Surgical has an analysts' consensus of $576.03 which suggests that it could grow by 11.38%. Given that Tandem Diabetes Care has higher upside potential than Intuitive Surgical, analysts believe Tandem Diabetes Care is more attractive than Intuitive Surgical.

Tandem Diabetes Care has a beta of 1.474, which suggesting that the stock is 47.439% more volatile than S&P 500. In comparison Intuitive Surgical has a beta of 1.697, suggesting its more volatile than the S&P 500 by 69.708%.

Tandem Diabetes Care has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Intuitive Surgical offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Tandem Diabetes Care pays -- of its earnings as a dividend. Intuitive Surgical pays out -- of its earnings as a dividend.

Tandem Diabetes Care quarterly revenues are $234.4M, which are smaller than Intuitive Surgical quarterly revenues of $2.3B. Tandem Diabetes Care's net income of -$130.6M is lower than Intuitive Surgical's net income of $698.4M. Notably, Tandem Diabetes Care's price-to-earnings ratio is -- while Intuitive Surgical's PE ratio is 75.83x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Tandem Diabetes Care is 1.34x versus 21.54x for Intuitive Surgical. Usually stocks with elevated PS ratios are considered overvalued.

Insulet has a net margin of -55.69% compared to Tandem Diabetes Care's net margin of 16.85%. Tandem Diabetes Care's return on equity of -81.14% beat Insulet's return on equity of 43.11%.

Tandem Diabetes Care has a consensus price target of $38.29, signalling upside risk potential of 91.62%. On the other hand Insulet has an analysts' consensus of $313.60 which suggests that it could grow by 25.31%. Given that Tandem Diabetes Care has higher upside potential than Insulet, analysts believe Tandem Diabetes Care is more attractive than Insulet.

Tandem Diabetes Care has a beta of 1.474, which suggesting that the stock is 47.439% more volatile than S&P 500. In comparison Insulet has a beta of 1.263, suggesting its more volatile than the S&P 500 by 26.336%.

Tandem Diabetes Care has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Insulet offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Tandem Diabetes Care pays -- of its earnings as a dividend. Insulet pays out -- of its earnings as a dividend.

Tandem Diabetes Care quarterly revenues are $234.4M, which are smaller than Insulet quarterly revenues of $597.5M. Tandem Diabetes Care's net income of -$130.6M is lower than Insulet's net income of $100.7M. Notably, Tandem Diabetes Care's price-to-earnings ratio is -- while Insulet's PE ratio is 43.22x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Tandem Diabetes Care is 1.34x versus 8.93x for Insulet. Usually stocks with elevated PS ratios are considered overvalued.